
By PR Newswire | Article Rating: |
|
February 7, 2014 06:30 AM EST | Reads: |
344 |

NEW DELHI, February 7, 2014 /PRNewswire/ --
KuicK Research releases "Global Orphan Drug Market Outlook 2018" research report offering comprehensive insight on recent trends, regulatory development related to US orphan drug market, Europe orphan drug market & Asia orphan drug market. Report also gives insight on more than 600 orphan drugs in clinical pipeline and 231 marketed orphan drugs.
Global Orphan Drug Market Report Findings:
- Orphan Designated Drugs in Clinical Phase: 600
- Marketed Orphan Designated Drugs: 281
- Highest Number of Drugs in Phase-2 Trial: 231
- US Dominates Clinical Trial Process: 350 in Pipeline (Research till Registration)
- Indication for Clinical Trials for Orphan Drug: More than 30% for Cancer Treatment
- Share of Biological in Orphan Drug: More than 60%
- Key Market: US (Sales > US$ 40 Billion)
The global pharmaceutical industry has been experiencing a slow growth in recent years owing to many factors such as expiration of patents, competition from generic drugs segment, exhausting pipelines, and an increasingly stringent regulatory framework. It is most likely that many blockbuster drugs would lose their exclusivity in the next 5 year horizon. Thus, due to significant competition from generics and the current economic situation, the focus area of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to investing in the new business model, which is also called orphan drugs. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.
The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market.
The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.
Key Highlights of Report
- Why Shift to Orphan Drugs
- Global & Regional Orphan Drug Market Overview
- Orphan Drug Designation Criteria Across US, Europe & Asia
- Market Specific Reimbursement Policy for US, Europe & Asia
- Regulatory Framework for US, Europe & Asia
- Orphan Drug Pipeline by Phase, Orphan Designated Indication & Country
- Competitive Landscape
Global Orphan Drug Report Table of Contents
1. Introduction to Orphan Drugs
2. Why Shift from Non-Orphan to Orphan Drugs?
3. Global Orphan Drug Market Outlook
4. US Orphan Drug Market Outlook
5. Europe Orphan Drug Market Outlook
6. Asia Orphan Drug Market Outlook
7. Global Orphan Drug Pipeline Insight by Phase, Orphan Designated Disease & Country
8. Key Issue to be Resolved
9. Competitive Landscape
For More information visit: http://www.kuickresearch.com/pharmaceutical-healthcare.php
Recent Published Research Reports:
- Global Radiopharmaceuticals Market Insight
- US Orphan Drug Market Outlook 2018
- US Cancer Vaccine Market Outlook 2018
- Europe Orphan Drug Market Outlook 2018
- Global Vaccine Market Pipeline Analysis
- Japan Cancer Drug Pipeline Analysis
- Global Monoclonal Antibodies Pipeline Analysis
- South Korea Biosimilar Market Analysis
For Report Query Contact:
Mr. Neeraj Chawla
Email: [email protected]
Tel: +91-11-47067990
SOURCE Kuick Research
Published February 7, 2014 Reads 344
Copyright © 2014 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
![]() Apr. 19, 2018 02:30 PM EDT Reads: 5,400 |
By Pat Romanski Apr. 19, 2018 02:00 PM EDT Reads: 1,967 |
By Pat Romanski Apr. 19, 2018 01:45 PM EDT Reads: 1,101 |
By Pat Romanski Apr. 19, 2018 01:30 PM EDT Reads: 2,044 |
By Elizabeth White Apr. 19, 2018 01:30 PM EDT Reads: 1,496 |
By Pat Romanski ![]() Apr. 19, 2018 01:30 PM EDT Reads: 1,582 |
By Liz McMillan Apr. 19, 2018 01:15 PM EDT Reads: 1,422 |
By Liz McMillan Apr. 19, 2018 01:15 PM EDT Reads: 1,561 |
By Liz McMillan ![]() Apr. 19, 2018 12:45 PM EDT Reads: 3,573 |
By Pat Romanski ![]() Apr. 19, 2018 12:45 PM EDT Reads: 5,169 |
By Yeshim Deniz Apr. 19, 2018 12:30 PM EDT Reads: 3,855 |
By Yeshim Deniz ![]() Apr. 19, 2018 12:30 PM EDT Reads: 1,617 |
By Yeshim Deniz Apr. 19, 2018 12:15 PM EDT Reads: 4,777 |
By Yeshim Deniz Apr. 19, 2018 12:00 PM EDT Reads: 1,635 |
By Liz McMillan ![]() Apr. 19, 2018 12:00 PM EDT Reads: 5,316 |